Exciting New Clinical Trial for Endometriosis Patients who Require IVF is now available at CCRM-Colorado
CCRM Colorado is conducting a randomized control trial to examine the effect of elagolix, a new oral medication which has been approved for treating endometriosis symptoms in comparison to leuprolide acetate on in vitro fertilization (IVF) cycle outcomes after transfer of euploid (chromosomally normal) embryos to patients with surgically diagnosed endometriosis.
- Age 22-42 at the time of initiation of IVF cycle
- Surgical diagnosis of endometriosis within 10 years of study entry
- Have at least one chromosomally normal embryo available for transfer
All participants must undergo a full evaluation for IVF to determine if they qualify for the study.
Patients who qualify for the study will receive one of the hormone drugs (elagolix or leuprolide acetate) for free and will receive a credit for comprehensive chromosome screening (CCS) as long as there is at least one euploid (chromosomally normal) embryo available for transfer.
To qualify for the study, contact us today to schedule an appointment with Dr. Eric Surrey at CCRM Colorado.